Fig. 5

Multi-omics study to explore the clinical predictive value of the model. (A) Illustrating the correlation between risk scores and sensitivity to chemotherapy drugs. (B) GSVA analysis results highlight differential pathway enrichment between high-risk and low-risk groups. (C) GSEA results further illustrate key signaling pathways differentially enriched between different risk groups. (D) Showing the molecular interaction networks of pathways associated with high-risk and low-risk groups.